Collegium Pharmaceutical, Inc. (COLL): Earnings News

COLL – Beats EPS loss estimates by $0.03 and slightly beats on revenues.

Key Facts Surrounding This News Item

  • COLL had a POWR Rating of B (Buy) coming into today.
  • COLL was 0.78% above its 10-Day Moving Average coming into today.
  • COLL was 2.81% above its 20-Day Moving Average coming into today.
  • COLL was 11.35% above its 50-Day Moving Average coming into today.
  • COLL was 35.87% above its 100-Day Moving Average coming into today.
  • COLL was 70.40% above its 200-Day Moving Average coming into today.
  • COLL had returned +34.18% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Collegium Pharmaceutical, Inc. (COLL)

Collegium Pharmaceuticals is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The company was founded in 2002 and is based in Canton, Massachusetts. View our full COLL ticker page with ratings, news, and more.

COLL at a Glance

COLL Current POWR Rating™
Overall POWR Rating™
COLL Current Price $18.71 0.75%
More COLL Ratings, Data, and News

COLL Price Reaction

The day of this event (Mar. 7, 2018)
COLL Closing Price$23.76 4.08%
COLL Volume715,600
28.11% from avg
Leading up to this event
COLL 1-mo return15.59%
After this event
COLL 1-day return15.20%
COLL 3-day return5.89%
COLL 5-day return9.30%

COLL Price Chart

The Top Stocks For 2019

More Collegium Pharmaceutical, Inc. (COLL) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All COLL News
Page generated in 1.0198 seconds.